NUBLEXA™ (Regorafenib) is a registered trademark of Bayer Zydus Pharma.
General warning: When observed in clinical trials, Regorafenib can cause severe fatal hepatotoxicity. The monitoring of hepatic function should be done during or after the treatment. If any elevation in liver enzymes or hepatocellular necrosis is found, then the rigorous dosage is reduced or discontinued depending upon the severity and persistence of the disease.
What is a Metastatic Colorectal Cancer?
Colorectal cancer is cancer that develops from the colon or rectum. It is also known as colon cancer, rectal cancer, or bowel cancer. Metastatic colorectal cancer spreads to two different parts of the body such as liver lungs or other organs. This cancer can also spread to the brain with the help of the spinal cord. The abundant widespread site of metastasis for colorectal cancer in the liver. Symptoms of colorectal cancer are weight loss, tiredness, bowel movement, blood in the stool.
Metastatic Colorectal Cancer Treatment: There are several treatment methods of metastatic colorectal cancer. Some of which are mentioned below:
- Radiation therapy: Radiation therapy is performed to reduce the size of the tumor or to completely destroy the cancer cell.
- Surgery: By surgery, tumors are removed from the liver and colon. This process reduces the pain and recovery time. If the tumor is big then Radiation therapy and chemotherapy are used to shrink the tumor before surgery.
- Clinical trials: Several tests are performed under the clinical trials to wipe up the cancer cell.
- Chemotherapy: chemotherapy is done before the surgery to shrink the size of the tumor. It can also be performed after surgery to wipe up all the remaining cancerous cells.
- Targeted therapy: few targeted drugs are used to destroy the cancer cell by blocking its activity.
- Immunotherapy: The immunotherapy body prepares its own cell to fight against cancer cells.
Regorafenib uses:Regorafenib is a kinase inhibitor class drug used to treat metastatic colorectal cancer. This drug is used to treat patients who have previously received treatment with oxaliplatin, fluoropyrimidine and irinotecan-based chemotherapy.